Anti-transthyretin antibodies
US11267877B2 · kind B2 · utility
1Cited by
15References
40Claims
0Family size
Inventors
Key dates
| Filing date | Oct 5, 2018 |
| Grant date | Mar 8, 2022 |
| Priority date | — |
| Expiry date | Oct 5, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, and for monitoring the efficacy of TTR therapies, among other applications.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.